AgingResearch.NewsJoin free

S-2P + montanide ISA51

S-2P + montanide ISA51 has been studied in 1 paper since 2025: none in people yet, 1 in animals. The research so far is in animals. The newest paper, Oct 3, 2025: “Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations”.

Intervention

1 paper studies it1 findingUpdated

See all 1 papers on S-2P + montanide ISA51

At a glance

The findings reach mice, none yet in people. 1 lab in 2 countries.

Mice: a single group. Cells, worms or flies and humans: nothing yet.

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

  • 1 lab in 2 countries
  • Funders: Ministry of Science and Technology of the People's Republic of China and 1 more
  • Animals1

What did studies of S-2P + montanide ISA51 find?

1

Studies of S-2P + montanide ISA51 measured 1 outcome; the most studied are humoral immunity (1 study).

humoral immunity

upin mice1

1 study

  1. S-2P + montanide ISA51 increases humoral immunity in mice.

    “Both S-2P:ISA720 and S-2P:ISA51 elicited potent humoral immunity, including cross-neutralizing antibodies against Omicron variants”

    Animals

    Adjuvant-dependent protection of SARS-CoV-2 spike vaccines: comparative immunogenicity of human-applicable formulations

    Journal of virology

Latest

Related